deltatrials
Terminated OBSERVATIONAL NCT02608528

Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy

Sponsor: Abramson Cancer Center at Penn Medicine

Conditions Non-Small Cell Lung Cancer (NSCLC)
Interventions [18F]fluoroglucose(FDG)
Updated 11 times since 2017 Last updated: Mar 16, 2021 Started: Oct 22, 2015 Primary completion: Jul 18, 2019 Completion: Jul 18, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Poor Accrual

Other terminated trials from Abramson Cancer Center at Penn Medicine

See all terminations from Abramson Cancer Center at Penn Medicine

Other Non-Small Cell Lung Cancer (NSCLC) trials with similar outcome

Browse all Non-Small Cell Lung Cancer (NSCLC) trials

A observational or N/A phase clinical study on Non-Small Cell Lung Cancer (NSCLC), this trial is terminated or withdrawn. The trial is conducted by Abramson Cancer Center at Penn Medicine and has accumulated 11 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotRecruiting~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotRecruiting~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshotRecruiting~Jul 2018 – ~Nov 2018 · 4 months · monthly snapshotUnknown Status~Nov 2018 – ~May 2020 · 18 months · monthly snapshotRecruiting~May 2020 – ~Jan 2021 · 8 months · monthly snapshotRecruiting~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshotRecruiting~Apr 2021 – ~May 2023 · 25 months · monthly snapshotTerminated~May 2023 – ~Jul 2024 · 14 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 24 months · monthly snapshotTerminated

Change History

11 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated

  3. May 2023 — Jul 2024 [monthly]

    Terminated

  4. Apr 2021 — May 2023 [monthly]

    Terminated

    Status: Recruiting → Terminated · Phase: NA → None

  5. Jan 2021 — Apr 2021 [monthly]

    Recruiting NA

▶ Show 6 earlier versions

  1. May 2020 — Jan 2021 [monthly]

    Recruiting NA

    Phase: EARLY_PHASE1 → NA

  2. Nov 2018 — May 2020 [monthly]

    Recruiting EARLY_PHASE1

    Status: Unknown Status → Recruiting

  3. Jul 2018 — Nov 2018 [monthly]

    Unknown Status EARLY_PHASE1

    Status: Recruiting → Unknown Status

  4. Jun 2018 — Jul 2018 [monthly]

    Recruiting EARLY_PHASE1

  5. Feb 2017 — Jun 2018 [monthly]

    Recruiting EARLY_PHASE1

    Phase: Phase 0 → EARLY_PHASE1

  6. Jan 2017 — Feb 2017 [monthly]

    Recruiting Phase 0

    First recorded

Oct 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Abramson Cancer Center at Penn Medicine
Data source: Abramson Cancer Center at Penn Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations